Skip to search boxSkip to navigationSkip to main content

Memory-related task performance by aged rhesus monkeys administered the muscarinic M1-preferring agonist, talsaclidine

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Abstract

Rationale: Muscarinic-acetylcholine receptor agonists are yet to be used clinically for the treatment of Alzheimer's disease (AD) even though laboratory evidence continues to support the potential for such an approach. Objectives: The purpose of this study was to evaluate the M1-preferring agonist talsaclidine in aged monkeys for effects on working memory. Methods: Three doses (0.6, 1.2, and 2.4 mg/kg, PO) of talsaclidine and two time intervals (45 min and 8 h) after drug administration were evaluated in seven aged rhesus macaques trained to perform a computer-assisted delayed matching-to-sample (DMTS) task. The relative effectiveness of talsaclidine was also compared with another M1-preferring agonist WAY-132983 that was previously studied in this laboratory. Results: Talsaclidine improved DMTS accuracy only during sessions initiated 8 h after administration of one of the doses (i.e. 0.6 mg/kg). The drug's enhanced effectiveness at the 8-h time point relative to the 45-min time point was surprising in view of the fact that plasma concentrations were highest 45 min after administration. A higher dose of talsaclidine (4.7 mg/kg) resulted in side effects (lethargy and excessive drooling) in some animals. Individualized optimal doses of talsaclidine were associated with 7.4% and 10.6% improvement in overall (all trials averaged) DMTS accuracy during the 45 min and 8 h post-administration sessions, respectively. Under similar experimental conditions WAY-132983 increased DMTS accuracy by up to 15.6% above control levels. Conclusion: Both talsaclidine and WAY-132983 provide at least modest improvements in DMTS accuracy in aged monkeys at some doses; however, challenges remain regarding the achievement of an adequate level of efficacy and reliability while minimizing side effects with these compounds. The positive findings do, however, support further study of the potential use of direct muscarinic agonists in the treatment age-related disorders of memory function.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 292-300 (9 pages)

Journal (Volume, Issue Number)

Psychopharmacology (Volume 162, Issue 3)

Publication milestones

  • Published - 2002

Publication status

Published - 2002

ISSN

0033-3158

Publication IDs

  • Scopus: 0036020324
  • PubMed: 12122487
  • ORCID: /0000-0003-2071-4767/work/68251921

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
1.01
SciVal
Author count
4
SciVal
citations
27
SciVal
Paper percentile
75
Fractional count
1
Fractional count
0.25
Fractional count
3
Fractional count
0.75
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
29
Captures
23
Mentions
1

Funding Details

Acknowledgements This work was supported in part by Boehringer Ingelheim, Ingelheim, Germany, the Alzheimer’s Association, and the Office of Research and Development, Medical Research Service, Department of Veterans Affairs. The authors also wish to acknowledge the bioanalytical work of Dr. Manfred Birkel, IKP, 67269 Grünstadt, Germany, and the technical support of primate technician Ms. Nancy Kille.
FundersFunding numbers
Alzheimer’s Association
-
Office of Research and Development, Medical Research Service
-
U.S. Department of Veterans Affairs
-
Boehringer Ingelheim
-